Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn L, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S. Lowe SL, et al. Among authors: stoltz rr. J Clin Pharmacol. 2014 Sep;54(9):968-78. doi: 10.1002/jcph.286. Epub 2014 Mar 26. J Clin Pharmacol. 2014. PMID: 24619932 Clinical Trial.
Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
Rorick-Kehn LM, Witcher JW, Lowe SL, Gonzales CR, Weller MA, Bell RL, Hart JC, Need AB, McKinzie JH, Statnick MA, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Stoltz RR, Wong CJ. Rorick-Kehn LM, et al. Among authors: stoltz rr. Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu036. doi: 10.1093/ijnp/pyu036. Int J Neuropsychopharmacol. 2014. PMID: 25637376 Free PMC article. Clinical Trial.
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.
Whiting RL, Darpo B, Chen C, Fletcher M, Combs D, Xue H, Stoltz RR. Whiting RL, et al. Among authors: stoltz rr. Clin Pharmacol Drug Dev. 2021 Aug;10(8):927-939. doi: 10.1002/cpdd.906. Epub 2021 Jan 18. Clin Pharmacol Drug Dev. 2021. PMID: 33462988 Free PMC article. Clinical Trial.
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ. Hussey EK, et al. Among authors: stoltz rr. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. Epub 2010 Mar 3. J Clin Pharmacol. 2010. PMID: 20200268 Clinical Trial.
37 results